In this CME activity Elias Jabbour, MD, reviews some of the recent clinical developments in advanced acute lymphoblastic leukemia. We invite you to learn more about the current and emerging standards of care, as well as safety and efficacy data from the select clinical trials, in patients with acute lymphoblastic leukemia.
- CD19-positive ALL
- A bispecific T-cell engager antibody
- Philadelphia chromosome-positive ALL
- Tyrosine kinase inhibitor
- Complete remission with full hematologic recovery
- Minimal residual disease
- Allogeneic stem-cell transplantation
Enter your information to begin.
This enduring activity was developed for a national audience of hematologist-oncologists and other clinicians interested in the management of patients with acute lymphoblastic leukemia.
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
0.75 AMA PRA Category 1 Credit™.
||December 07, 2018
||December 06, 2019
Other Healthcare Providers
This enduring activity is supported by an educational grant from Takeda Oncology.
This activity is supported by educational funding provided by Amgen.